Find Clinical Trials

All CategoriesMedical Conditions»Digestive Disorders»Esophagus



Join Paid Clinical Trials



  • Condition:   Barrett's Esophagus
    Intervention:  
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Condition:   Barrett's Esophagus
    Intervention:   Device: Sponge capsule
    Sponsors:   Mayo Clinic;   Exact Sciences Corporation
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Drug: KSP/QRH dimer
    Sponsor:   University of Michigan
    Not yet recruiting

  • Condition:   Barrett's Esophagus
    Intervention:  
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Drug: Multiplexed heptapeptides
    Sponsor:   University of Michigan
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Device: Tethered Capsule Endomicroscopy (TCE)
    Sponsors:   Massachusetts General Hospital;   Columbia University;   Mayo Clinic;   Kansas City Veteran Affairs Medical Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Barrett Esophagus
    Interventions:   Procedure: Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI);   Device: Olympus Disposable Distal Attachment Cap
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Barrett's Esophagus
    Intervention:   Device: Experimental OFDI Imaging
    Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Barretts Esophagus With Dysplasia
    Intervention:   Device: The EndoRotor®
    Sponsors:   Foundation for Liver Research;   Interscope, Inc.
    Recruiting

  • Condition:   Barretts Esophagus With Dysplasia
    Intervention:   Drug: Alginates
    Sponsor:   Medical University of South Carolina
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Device: The Nvision VLE Imaging System
    Sponsors:   Mayo Clinic;   American Society for Gastrointestinal Endoscopy
    Recruiting

  • Conditions:   Barrett's Esophagus;   High-grade Dysplasia in Barrett Esophagus;   Low Grade Dysplasia in Barrett Esophagus
    Interventions:   Device: Hybrid argon plasma ablation (HAPC);   Device: Radiofrequency ablation (RFA)
    Sponsors:   Erbe Elektromedizin GmbH;   Erbe USA Incorporated;   Kansas City Veteran Affairs Medical Center;   Emissary International LLC
    Not yet recruiting

  • Condition:   Barrett's Esophagus
    Intervention:   Device: OFDI Capsule Marking
    Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Barrett's Esophagus;   Esophageal Neoplasm
    Interventions:   Device: Balloon Capsule Device;   Procedure: Endoscopy
    Sponsors:   University Hospitals Cleveland Medical Center;   Case Western Reserve University;   Washington University School of Medicine;   Fred Hutchinson Cancer Research Center;   University of Washington;   Mercy Medical Center;   Johns Hopkins University;   Mayo Clinic;   University of North Carolina, Chapel Hill;   The Cleveland Clinic;   University of Pennsylvania;   Columbia University;   VA Puget Sound Health Care System
    Recruiting

  • Condition:   Barrett Esophagus Adenocarcinoma
    Interventions:   Procedure: Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.;   Device: Endoscopic resection at month 2 and month 4
    Sponsor:   Institut Paoli-Calmettes
    Recruiting

  • Conditions:   Barrett's Esophagus;   Esophageal Adenocarcinoma
    Intervention:   Other: EMR and RFA effect on stem cell marker expression in BE/EAC
    Sponsor:   University of Oklahoma
    Recruiting

  • Conditions:   Barrett's Esophagus;   Esophageal Cancer
    Interventions:   Procedure: Endoscopic eradication therapies (EET);   Procedure: Esophagectomy;   Drug: Chemotherapy;   Radiation: Radiation
    Sponsors:   University of Colorado, Denver;   Feinberg School of Medicine, Northwestern University;   University of California, Los Angeles;   H. Lee Moffitt Cancer Center and Research Institute;   California Pacific Medical Center
    Recruiting

  • Conditions:   Barrett Esophagus;   Barrett Adenocarcinoma;   Esophagus Neoplasm
    Interventions:   Procedure: Endoscopic mucosal resection;   Procedure: Endoscopic submucosal dissection
    Sponsor:   Universitätsklinikum Hamburg-Eppendorf
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Other: Video intervention
    Sponsor:   Northwestern University
    Recruiting

  • Condition:   Advanced Esophagus Cancer
    Intervention:   Drug: Apatinib
    Sponsor:   Affiliated Hospital of North Sichuan Medical College
    Not yet recruiting

  • Condition:   Squamous Cell Carcinoma of the Esophagus
    Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
    Sponsors:   IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest;   Eli Lilly and Company;   Trium Analysis Online GmbH
    Recruiting

  • Condition:   Cancer of Esophagus
    Intervention:  
    Sponsors:   Aarhus University Hospital Skejby;   Danish Cancer Society
    Recruiting

  • Condition:   Esophagus Squamous Cell Carcinoma
    Intervention:   Drug: raltitrexed
    Sponsor:   Huai'an First People's Hospital
    Recruiting

  • Condition:   Barretts Esophagus With Dysplasia
    Interventions:   Device: EndoRotor Mucosal Resection System;   Device: Continued Ablation
    Sponsor:   Interscope, Inc.
    Recruiting

  • Condition:   Barrett's Esophagus With Dysplasia
    Interventions:   Device: Mucosal Impedance;   Other: Research Biopsies;   Device: Volumetric Laser Endomicroscopy
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Barrett Esophagus;   Esophageal Neoplasms;   Reflux Esophagitis
    Intervention:   Device: Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source
    Sponsor:   University of Cambridge
    Recruiting

  • Condition:   Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
    Intervention:   Drug: PDR001+MCS110
    Sponsor:   Yonsei University
    Not yet recruiting

  • Conditions:   Barrett's Esophagus;   Neoplasms;   Gastroesophageal Reflux
    Intervention:  
    Sponsors:   Midwest Biomedical Research Foundation;   Kansas City Veteran Affairs Medical Center
    Recruiting

  • Conditions:   Barrett's Esophagus;   Gastroesophageal Reflux Disease;   Esophageal Adenocarcinoma
    Intervention:  
    Sponsors:   Midwest Biomedical Research Foundation;   Kansas City Veteran Affairs Medical Center
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:  
    Sponsors:   Geisinger Clinic;   Medical University of South Carolina;   Long Island Jewish Medical Center;   Pentax Medical;   Virginia Commonwealth University
    Recruiting

  • Condition:   Barrett's Esophagus
    Intervention:   Other: Biopsies with histopathology
    Sponsor:   Institute for Clinical and Experimental Medicine
    Recruiting

  • Condition:   Barrett Esophagus
    Intervention:   Device: CryoBalloon Ablation System
    Sponsor:   C2 Therapeutics, Inc.
    Recruiting

  • Condition:   Barrett's Esophagus
    Intervention:   Drug: Proflavine, high resolution imaging
    Sponsors:   Anandasabapathy, Sharmila, M.D.;   William Marsh Rice University;   Baylor College of Medicine
    Recruiting

  • Condition:   Barrett Esophagus
    Interventions:   Drug: Bevacizumab-IRDye800CW;   Diagnostic Test: Fluorescence endoscopy
    Sponsors:   University Medical Center Groningen;   Helmholtz Zentrum München
    Not yet recruiting

  • Condition:   Esophagus Cancer
    Intervention:   Procedure: preoperative enhanced chest CT examination
    Sponsor:   Beijing Cancer Hospital
    Recruiting

  • Conditions:   Small Cell Carcinoma of Esophagus;   Advanced Cancer
    Intervention:   Drug: Toripalimab
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Condition:   Esophagus
    Interventions:   Procedure: Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA);   Procedure: Contrast-Enhanced Ultrasound;   Procedure: Fine-Needle Aspiration;   Drug: Sonazoid (Perflubutane)
    Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Barrett Esophagus;   Esophageal Cancer
    Intervention:   Diagnostic Test: endoscopy
    Sponsors:   University of Exeter;   University of Bristol;   Gloucestershire Hospitals NHS Foundation Trust
    Not yet recruiting

  • Condition:   Esophagus Cancer
    Intervention:   Procedure: Single-hole inflatable mediastinal mirror
    Sponsor:   Qingdong Cao
    Recruiting

  • Condition:   Esophagus Disorder
    Interventions:   Device: Radiofrequency ablation;   Procedure: esophagoscopy
    Sponsor:   Medical University of Vienna
    Recruiting

  • Condition:   Esophagus Cancer
    Intervention:   Radiation: Proton radiation
    Sponsor:   Loma Linda University
    Recruiting

  • Conditions:   Advanced Solid Tumors;   Advanced Esophagus Cancer and Squamous Cell Carcinoma of the Esophageal Junction
    Intervention:   Drug: CYH33 for tablet
    Sponsor:   ShangHai HaiHe Pharmaceutical
    Recruiting

  • Condition:   Eosinophilic Esophagitis
    Intervention:   Device: SECM Capsule
    Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Esophageal Cancer
    Interventions:   Radiation: Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph node;   Radiation: Boost;   Drug: chemotherapy: FOLFOX 4
    Sponsors:   Centre Georges Francois Leclerc;   National Cancer Institute, France;   UNICANCER;   SFRO:French Society of Radiation Oncology;   Federation Francophone de Cancerologie Digestive
    Recruiting

  • Condition:   Eosinophillic Esophagitis
    Intervention:   Device: SECM capsule
    Sponsor:   Massachusetts General Hospital
    Not yet recruiting

  • Conditions:   Lung Cancer;   Esophageal Cancer;   Mesothelioma;   Gastrointestinal Neoplasms;   Breast Cancer
    Intervention:   Drug: Mithramycin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Optical Enhancement Endoscopy
    Interventions:   Device: first OE;   Device: first WLI
    Sponsor:   Shandong University
    Recruiting

  • Condition:   Non-Small Cell Lung Cancer
    Interventions:   Radiation: Conventional radiotherapy;   Radiation: Esophageal-Sparing Intensity-Modulated Radiotherapy
    Sponsor:   Lawson Health Research Institute
    Recruiting

  • Condition:   Head & Neck Cancer
    Intervention:   Drug: nanoliposomal irinotecan
    Sponsors:   National Health Research Institutes, Taiwan;   China Medical University Hospital;   Tri-Service General Hospital;   Taipei Veterans General Hospital, Taiwan;   National Cheng-Kung University Hospital
    Not yet recruiting

  • Conditions:   Esophageal Adenocarcinoma (UICC TNM7);   Adenocarcinoma of the Esophagogastric Junction
    Interventions:   Drug: 5-Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Neoadjuvant radiation
    Sponsors:   University Hospital Freiburg;   Clinical Trials Unit Freiburg;   CTC laboratories at University of Hamburg and University of Freiburg;   ESOPEC reference pathology at the University of Freiburg;   Universitätsklinikum Leipzig, Universitäres Krebszentrum (UCCL)
    Recruiting

  • Condition:   Gastroesophageal Reflux
    Intervention:  
    Sponsor:   Centre Hospitalier Universitaire de Nice
    Recruiting

  • Conditions:   Barrett's Esophagus Without Dysplasia;   Barrett's Esophagus With Dysplasia;   Barrett's Esophagus With Low Grade Dysplasia;   Barrett's Esophagus With High Grade Dysplasia;   Barrett's Esophagus With Dysplasia, Unspecified
    Interventions:   Diagnostic Test: IRIS (Intelligent real-time image segmentation);   Diagnostic Test: VLE (Volumetric laser endomicroscopy)
    Sponsors:   Northwell Health;   NinePoint Medical
    Recruiting

  • Conditions:   Barrett Esophagus;   Esophageal Dysplasia;   Esophageal Adenocarcinoma
    Intervention:   Procedure: Diagnostic Test
    Sponsor:   CDx Diagnostics
    Recruiting

  • Conditions:   Esophagus Cancer;   Esophagogastric Junction Cancer
    Interventions:   Device: MRI and CT;   Radiation: Ratiotherapy;   Drug: Paclitaxel, platinum-based drug
    Sponsor:   Chinese Academy of Medical Sciences
    Recruiting

  • Conditions:   Gastric Cancer;   Esophagus Cancer
    Intervention:   Drug: Oxaliplatin+Capecitabine+Pembrolizumab
    Sponsors:   Duke University;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Cancer of Esophagus;   Cancer, Lung
    Interventions:   Procedure: whole body electromyostimulation exercise;   Procedure: protein-rich nutrition therapy
    Sponsor:   University of Erlangen-Nürnberg Medical School
    Recruiting

  • Conditions:   Cancer of Stomach;   Cancer of Esophagus
    Intervention:  
    Sponsor:   Parc de Salut Mar
    Recruiting

  • Conditions:   Diseases of Oesophagus Stomach and Duodenum;   Advanced Gastroesophageal Adenocarcinoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Barrett Esophagus;   Dysplasia;   Esophageal Adenocarcinoma;   Esophageal Squamous Cell Carcinoma;   Gastroesophageal Reflux Disease;   Metaplasia
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Device: Swallowable Sponge Cell Sampling Device
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Esophagus Cancer;   Esophageal Cancer;   Cancer of the Esophagus
    Interventions:   Radiation: Proton beam therapy;   Other: Patient-Reported Outcome Measures
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Esophagus Squamous Cell Carcinoma (SCC);   Metastatic Cancer
    Interventions:   Drug: Docetaxel-PM;   Drug: Oxaliplatin
    Sponsor:   Sung Yong Oh
    Recruiting

  • Conditions:   Esophageal Cancer;   Squamous Cell Esophagus Cancer;   Adenocarcinoma Esophagus
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Barrett Esophagus;   Gastroesophageal Reflux;   Esophageal Dysplasia;   Esophageal Diseases
    Intervention:  
    Sponsors:   CDx Diagnostics;   University of North Carolina, Chapel Hill
    Recruiting

  • Conditions:   Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer;   Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer;   Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
    Intervention:   Other: data collection
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Gastric Cardia;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIC Esophageal Cancer
    Interventions:   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sarcoma;   Rectal Carcinoma;   Esophagus Cancer
    Intervention:   Radiation: Standard treatment
    Sponsor:   Centre Leon Berard
    Recruiting

  • Conditions:   Cancer of Pancreas;   Cancer of Stomach;   Cancer of Esophagus
    Intervention:   Other: Anticipatory care planning letter
    Sponsors:   NHS Lothian;   NHS Fife
    Recruiting

  • Conditions:   Gastroesophageal Reflux Disease;   Barrett Esophagus;   Laryngopharyngeal Reflux;   Esophagitis
    Intervention:  
    Sponsors:   Johns Hopkins University;   EndoGastric Solutions
    Not yet recruiting

  • Conditions:   Adenocarcinoma of the Oesophagus;   Adenocarcinoma of the Gastro-oesophageal Junction;   Adenocarcinoma of the Stomach
    Interventions:   Drug: Capecitabine;   Drug: MEDI4736;   Drug: Trastuzumab;   Drug: Rucaparib
    Sponsors:   Royal Marsden NHS Foundation Trust;   MedImmune LLC;   Clovis Oncology, Inc.
    Recruiting

  • Condition:   Morbid Obesity
    Intervention:   Diagnostic Test: Gastroscopy
    Sponsor:   University Hospital, Basel, Switzerland
    Recruiting

  • Conditions:   Esophageal Neoplasms;   Esophageal Cancer;   Cancer of the Esophagus
    Interventions:   Drug: Pembrolizumab;   Radiation: Brachytherapy;   Procedure: Endoscopic biopsy;   Procedure: Computed tomography-guided biopsy;   Procedure: Peripheral blood collection
    Sponsors:   Washington University School of Medicine;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Leakage After Esophagectomy;   Leakage After Gastrectomy;   Perforation of the Esophagus
    Intervention:   Device: Eso-SPONGE® vacuum treatment
    Sponsors:   Aesculap AG;   Universitätsklinikum Kiel
    Recruiting

  • Conditions:   Esophagogastric Cancer;   Moderate to Severe Dysphagia
    Intervention:   Drug: WST 11-mediated VTP therapy
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Weizmann Institute of Science;   Steba Biotech S.A.
    Recruiting

  • Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Gastric Adenocarcinoma;   Gastric Squamous Cell Carcinoma;   Metastatic Malignant Neoplasm in the Stomach;   Stage IV Esophageal Adenocarcinoma;   Stage IV Esophageal Squamous Cell Carcinoma
    Interventions:   Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pulmonary Metastases From Cancers;   Mediastinal or Chest Wall Neoplasms;   Malignant Pleural Mesotheliomas NOS;   Esophageal Cancers NOS;   Lung Cancer NOS
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Dysphagia;   Airway Aspiration;   Airway Penetration
    Interventions:   Other: Slower Flow Rate;   Other: Thickened Formula
    Sponsors:   Sudarshan Jadcherla;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Ohio State University;   Medical College of Wisconsin
    Recruiting

  • Conditions:   Barrett Esophagus;   Gastric Antrectomy Partial;   Biliary Duct Stricture;   Pancreatic Duct Stricture;   Colorectal Polyps;   Esophageal Epidermoid Cancer in Pts With Head and Neck Cancer
    Intervention:   Procedure: Confocal endomicroscopy
    Sponsor:   Fauze Maluf Filho
    Recruiting

  • Condition:   Esophageal Cancer
    Interventions:   Procedure: Robotic esophagectomy;   Procedure: Thoracolaparoscopic esophagectomy
    Sponsor:   GEM Hospital & Research Center
    Recruiting

  • Conditions:   Caustic Esophageal Injury;   Esophageal Stenosis;   Pharyngeal Stenosis
    Interventions:   Drug: Methylprednisolone;   Other: Placebo
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

  • Conditions:   Oesophageal Adenocarcinoma;   Chemotherapy Effect;   Surgery
    Intervention:   Behavioral: Exercise prehabilitation during chemotherapy before surgery
    Sponsor:   Guy's and St Thomas' NHS Foundation Trust
    Recruiting

  • Condition:   Surgical Anastomosis
    Intervention:   Procedure: Hyperspectral Imaging
    Sponsor:   University of Leipzig
    Recruiting

  • Conditions:   Atrial Fibrillation;   Catheter Ablation;   Esophageal Fistula;   Esophageal Diseases;   Arrhythmias, Cardiac
    Intervention:   Device: EnsoETM
    Sponsor:   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    Recruiting

  • Condition:   Esophageal Neoplasm
    Interventions:   Device: Endodrill Biopsy;   Device: Conventional Biopsy forceps
    Sponsor:   Region Skane
    Recruiting

  • Conditions:   Esophagus Cancer;   Esophagogastric Junction Cancer;   Radiotherapy; Complications;   Chemoradiation
    Interventions:   Radiation: SIB-IMRT;   Drug: S-1
    Sponsors:   Chinese Academy of Medical Sciences;   Hebei Medical University Fourth Hospital;   Tianjin Medical University Cancer Institute and Hospital;   Anyang Tumor Hospital;   The First Affiliated Hospital with Nanjing Medical University;   Affiliated Hospital of Hebei University;   Fujian Cancer Hospital;   Tengzhou Central People's Hospital;   The First Affiliated Hospital of Zhengzhou University;   The Affiliated Hospital of Inner Mongolia Medical University;   Sichuan Cancer Hospital and Research Institute
    Recruiting

  • Conditions:   Venous Thromboembolism;   Esophagus Cancer;   Bleeding;   Chemotherapy Effect
    Intervention:   Other: Venous thromboembolic event, arterial thromboembolic event, bleeding events
    Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    Recruiting

  • Conditions:   Esophageal Adenocarcinoma;   Esophagus SCC;   Cholangiocarcinoma;   Urothelial/Bladder Cancer, Nos;   Endometrial Cancer
    Intervention:   Drug: Abemaciclib
    Sponsors:   Jules Bordet Institute;   Eli Lilly and Company
    Recruiting

  • Conditions:   Circulatory; Change;   Microcirculation
    Intervention:  
    Sponsor:   Oslo University Hospital
    Recruiting

  • Conditions:   GORD;   Oesophageal Cancer;   Oesophageal Reflux;   Gastric Cancer;   Gastro Esophageal Reflux;   Oesophageal Carcinoma;   Barrett Esophagus;   Esophagitis
    Intervention:   Diagnostic Test: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
    Sponsor:   Imperial College London
    Recruiting

  • Conditions:   Cancer;   Esophagus Squamous Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck;   Anal Canal Squamous Cell Carcinoma;   Metastatic Cancer
    Intervention:  
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Esophageal Neoplasms;   Cancer of Esophagus;   Cancer of the Esophagus;   Esophageal Cancer;   Esophagus Cancer;   Neoplasm, Esophageal;   Esophagectomy
    Intervention:   Other: Mayo Clinic Conduit Report Card Questionnaires
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Esophageal Disease
    Intervention:  
    Sponsors:   University Hospital, Lille;   French Eso-Gastric Tumors Working Group;   National Cancer Institute, France
    Recruiting

  • Conditions:   Cancer;   Cancer of Pancreas;   Cancer of Liver;   Cancer of Esophagus;   Cancer of Stomach;   Cancer, Metastatic
    Intervention:  
    Sponsor:   Rigshospitalet, Denmark
    Recruiting

  • Conditions:   Esophageal Cancer;   GastroEsophageal Cancer
    Interventions:   Drug: APX005M;   Radiation: Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Procedure: Surgical resection of tumor
    Sponsors:   University of California, San Francisco;   Apexigen, Inc.
    Recruiting

  • Conditions:   Positive-Pressure Respiration/Methods;   Esophagus/Physiopathology;   Pleura/Physiopathology;   Gynecologic Surgical Procedures;   Laparoscopy;   Humans;   Female
    Intervention:   Procedure: PEEP setting based on esophageal pressure measured
    Sponsor:   Mahidol University
    Recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Hepatoma;   Gastric Cancer;   Pancreatic Cancer;   Mesothelioma;   Colorectal Cancer;   Esophagus Cancer;   Lung Cancer;   Glioma;   Melanoma;   Synovial Sarcoma;   Ovarian Cancer;   Renal Carcinoma
    Intervention:   Biological: CAR-T cell immunotherapy
    Sponsors:   Shenzhen BinDeBio Ltd.;   The First Affiliated Hospital of Zhengzhou University
    Recruiting

  • Conditions:   Ovary Cancer;   Cervix Cancer;   Endometrium Cancer;   Bladder Cancer;   Prostate Cancer;   Esophagus Cancer;   Lung Cancer, Nonsmall Cell;   Squamous Cell Carcinoma of the Head and Neck
    Intervention:   Drug: Tisotumab Vedotin
    Sponsor:   Genmab
    Recruiting

  • Conditions:   Cancer, All Types;   Cancer of Liver;   Cancer of Stomach;   Cancer of Head and Neck;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Colon;   Cancer Skin;   Cancer of Cervix;   Cancer, Metastatic;   Cancer of Larynx;   Cancer of Neck;   Cancer of Lung;   Cancer of Brain and Nervous System;   Cancer of Vulva, Disseminated;   Cancer of Pancreas;   Sarcoma;   GIST;   Small-cell Lung Cancer;   Adenocarcinoma Lung;   Cancer of Prostate;   Cancer, Advanced;   Adrenal Cancer;   Testicular Cancer;   Uterine Cancer;   Bronchoalveolar Cell Lung Cancer;   Cancer Unknown Primary;   Glioblastoma Multiforme;   Oligodendroglioma;   Breast Cancer;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Cholangiocarcinoma;   Squamous Cell Carcinoma;   Transitional Cell Carcinoma;   Cancer, Other;   Cancer, Anal;   Melanoma;   Cancer, Bile Duct;   Cancer, Bladder;   Cancer Cords Vocal;   Cancers Cell Neuroendocrine;   Cancer Differentiated Poorly;   Cancer, Anaplastic Thyroid
    Intervention:  
    Sponsors:   SpeciCare;   Dana-Farber Cancer Institute;   Kalispell Regional Medical Center;   Georgia Institute of Technology;   Ontario Institute for Cancer Research;   SEngine Precision Medicine;   Helomics
    Recruiting

  • Conditions:   Cancer, Metastatic;   Cancer;   Cancer of Pancreas;   Cancer of Liver;   Cancer of Stomach;   Cancer Liver;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Cervix;   Cancer of Colon;   Cancer of Larynx;   Cancer, Lung;   Cancer, Breast;   Cancer, Advanced;   Cancer Prostate;   Cancer of Neck;   Cancer of Skin;   Neuroendocrine Tumors;   Carcinoma;   Mismatch Repair Deficiency;   BRCA Gene Rearrangement;   Non Hodgkin Lymphoma;   Leukemia;   Non Small Cell Lung Cancer;   Cholangiocarcinoma;   Glioblastoma;   Central Nervous System Tumor;   Melanoma;   Urothelial Carcinoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Testicular Cancer;   Breast Cancer
    Intervention:   Other: Clinical Trial Matching
    Sponsor:   Massive Bio, Inc.
    Recruiting

  • Conditions:   Cancer of Unknown Origin;   Cancer Refractory;   Cancer of Stomach;   Cancer Head Neck;   Cancer of Skin;   Cancer, Lung;   Cancer Colorectal;   Cancer of Esophagus;   Cancer, Bladder;   Cancer, Uterus;   Cancer Cervix;   Cancer Liver;   Cancer, Kidney;   Cancer, Breast;   Hematologic Neoplasms
    Intervention:   Other: Genomic testing
    Sponsors:   Arbeitsgemeinschaft medikamentoese Tumortherapie;   Roche Pharma AG
    Recruiting

  • Conditions:   Radiation Therapy;   Cancer;   Cancer of Anus;   Cancer of Bladder;   Cancer of Cervix;   Cancer of Colon;   Cancer of Rectum;   Cancer of Esophagus;   Cancer of Gallbladder;   Cancer of Liver;   Cancer of Ovary;   Cancer of Pancreas;   Cancer of Prostate;   Cancer of Kidney and Renal Pelvis;   Cancer of Stomach;   Cancer of Testis;   Cancer of Uterus;   Cancer of Uterus and Cervix;   Cancer of Kidney
    Intervention:  
    Sponsors:   DxTerity Diagnostics;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anatomic Stage II Breast Cancer;   Anatomic Stage IIA Breast Cancer;   Anatomic Stage IIB Breast Cancer;   Anatomic Stage III Breast Cancer;   Anatomic Stage IIIA Breast Cancer;   Anatomic Stage IIIB Breast Cancer;   Anatomic Stage IIIC Breast Cancer;   Clinical Stage II Esophageal Adenocarcinoma;   Clinical Stage II Esophageal Squamous Cell Carcinoma;   Clinical Stage II Gastric Cancer;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIA Esophageal Adenocarcinoma;   Clinical Stage IIA Gastric Cancer;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma;   Clinical Stage IIB Esophageal Adenocarcinoma;   Clinical Stage IIB Gastric Cancer;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Esophageal Adenocarcinoma;   Clinical Stage III Esophageal Squamous Cell Carcinoma;   Clinical Stage III Gastric Cancer;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma;   Distal Esophagus Squamous Cell Carcinoma;   Esophageal Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Limited Stage Small Cell Lung Carcinoma;   Malignant Solid Neoplasm;   Non-Small Cell Lung Carcinoma;   Pancreatic Adenocarcinoma;   Pathologic Stage II Esophageal Adenocarcinoma;   Pathologic Stage II Esophageal Squamous Cell Carcinoma;   Pathologic Stage II Gastric Cancer;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIA Esophageal Adenocarcinoma;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIA Gastric Cancer;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIB Esophageal Adenocarcinoma;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIB Gastric Cancer;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Esophageal Adenocarcinoma;   Pathologic Stage III Esophageal Squamous Cell Carcinoma;   Pathologic Stage III Gastric Cancer;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIA Esophageal Adenocarcinoma;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIA Gastric Cancer;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIB Esophageal Adenocarcinoma;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma;   Pathologic Stage IIIB Gastric Cancer;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage IIIC Gastric Cancer;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage II Gastric Cancer;   Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage III Gastric Cancer;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma;   Progesterone Receptor Negative;   Prognostic Stage II Breast Cancer;   Prognostic Stage IIA Breast Cancer;   Prognostic Stage IIB Breast Cancer;   Prognostic Stage III Breast Cancer;   Prognostic Stage IIIA Breast Cancer;   Prognostic Stage IIIB Breast Cancer;   Prognostic Stage IIIC Breast Cancer;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Lung Cancer;   Stage II Pancreatic Cancer;   Stage IIA Lung Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Lung Cancer;   Stage IIB Pancreatic Cancer;   Stage III Lung Cancer;   Stage IIIA Lung Cancer;   Stage IIIB Lung Cancer;   Stage IIIC Lung Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Ifetroban Sodium;   Other: Placebo
    Sponsors:   Vanderbilt-Ingram Cancer Center;   Cumberland Pharmaceuticals
    Recruiting

  • Conditions:   Clinical Stage I Esophageal Adenocarcinoma AJCC v8;   Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage I Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Thoracic Esophagus Squamous Cell Carcinoma
    Interventions:   Drug: Carboplatin;   Procedure: Esophagectomy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Paclitaxel;   Radiation: Proton Beam Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   a. Colorectal Cancer;   b. High Grade Serous Ovarian Cancer;   c. Non Small-cell Lung Cancer (Squamous Cell Variant);   d. Squamous Carcinoma of the Oesophagus;   e. Squamous Carcinoma of the Head and Neck (HPV Negative);   f. Urothelial Cancer;   g. Breast Cancer (Triple Negative Type);   h. Pancreatic Cancer
    Intervention:   Drug: LY3143921 hydrate
    Sponsor:   Cancer Research UK
    Recruiting

  • Conditions:   Gastroesophageal Reflux;   GERD
    Interventions:   Procedure: Confocal endomicroscopy;   Procedure: Mucosal impedance;   Procedure: Research biopsies;   Procedure: Bravo ambulatory pH monitor
    Sponsor:   Mayo Clinic
    Recruiting

  • Condition:   Advanced Esophageal Cancer
    Interventions:   Biological: Anti-MUC1 CAR-T cells;   Biological: PD-1 knockout Engineered T cells;   Combination Product: CAR-T combined with PD-1 Knockout T cells
    Sponsors:   The First Affiliated Hospital of Guangdong Pharmaceutical University;   Guangzhou Anjie Biomedical Technology Co., Ltd.
    Recruiting

  • Conditions:   Esophageal Stricture;   Eosinophilic Esophagitis;   Zenkers Diverticulum;   Schatzki Ring
    Intervention:   Device: EndoFLIP
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Esophageal Cancer;   Gastric Cancer
    Intervention:   Drug: Afatinib and Paclitaxel
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Boehringer Ingelheim;   University of Southern California;   Dana-Farber Cancer Institute;   United States Department of Defense
    Recruiting

  • Condition:   Esophageal Squamous Cell Carcinoma (ESCC)
    Interventions:   Drug: BGB-A317;   Drug: Paclitaxel, or Docetaxel, or Irinotecan
    Sponsor:   BeiGene
    Recruiting

Login to Get Started